Can Resveratrol Treatment Control the Progression of Induced Periodontal Disease? A Systematic Review and Meta-Analysis of Preclinical Studies

source extracted confidence: high 2026-04-09
#animals #anti-inflammatory-agents-non-steroidal #periodontal-diseases #resveratrol

Can Resveratrol Treatment Control the Progression of Induced Periodontal Disease? A Systematic Review and Meta-Analysis of Preclinical Studies

Andrade et al., 2019 | Nutrients | Meta Analysis

Citation

Andrade Eric Francelino, Orlando Débora Ribeiro, ... Pereira Luciano José. Can Resveratrol Treatment Control the Progression of Induced Periodontal Disease? A Systematic Review and Meta-Analysis of Preclinical Studies. Nutrients. 2019-Apr-26;11(5). doi:10.3390/nu11050953

Abstract

Resveratrol is an anti-inflammatory compound found in several foods. Periodontal disease (PD) is associated to other systemic diseases, and inflammation may be responsible for the association. Consequently, controlling inflammation not only may benefit oral health but also may assist with the management of other chronic inflammatory conditions. We aimed to investigate the effects of resveratrol administration on PD control in preclinical studies. A systematic search was performed for scientific articles using both electronic databases and a manual search using combinations of the following keywords: "resveratrol" OR "3,5,4'-trihydroxystilbene" AND "periodontal disease" OR "periodontitis" OR "gingivitis". Only in vivo original studies investigating resveratrol treatment on experimental animal models of PD were selected. A quality assessment of the studies was performed using the Animal Research Reporting In Vivo Experiment (ARRIVE) guidelines, and the risk of bias was assessed using the Syrcle tool. The search returned 570 articles, and 11 matched the inclusion criteria. A meta-analysis showed that resveratrol treatment attenuated alveolar bone loss (τ2 = 0.0041; 95% CI: -0.14; -0.04). The ARRIVE criteria reported a good quality of studies in general (mean score 28.5 ± 2.5). However, five Syrcle domains indicated a high risk of bias or did not present information clearly. We concluded that, in preclinical studies, resveratrol treatment prevented PD progression.

Key Findings

We concluded that, in preclinical studies, resveratrol treatment prevented PD progression.

Outcomes Measured

  • inflammatory markers

Population

Field Value
Population See abstract
Sample Size See abstract
Age Range See abstract
Condition inflammation

MeSH Terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal
  • Periodontal Diseases
  • Resveratrol

Evidence Classification

  • Level: Meta Analysis
  • Publication Types: Journal Article, Meta-Analysis, Systematic Review
  • Vertical: resveratrol

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09